Navigation Links
MULTI-LINK OTW PENTA Coronary Stent System

ProductsMULTI-LINK OTW PENTA Coronary Stent System
Company Guidant Corporation
Item MULTI-LINK OTW PENTA Coronary Stent System
Features Consistent cell size and rounded struts for easy access. Corrugated ring design together with ACCESS-LINK Technology allows for good stent cell expansion. THE WRAP Balloon with S.T.E.P. Technology provides improved re-wrap and lower profile upon deflation for smooth pullback into 5F guides. S.T.E.P. Technology minimizes vessel Dialation outside the stent upon expansion.
Description The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter.
Info Guidant Corporation
Customer Service: (317) 971-2000
Web site: http://www.guidant.com/

Related medicine products :

1. MULTI-LINK OTW PIXEL Coronary Stent System
2. MULTI-LINK RX PIXEL Coronary Stent System
3. MULTI-LINK OTW ZETA Coronary Stent System
4. MULTI-LINK RX PENTA Coronary Stent System
5. MULTI-LINK RX ZETA Coronary Stent System
6. MULTI-LINK OTW ULTRA Coronary Stent System
7. MULTI-LINK RX ULTRA Coronary Stent System
8. MULTI-LINK MINI VISIONCoronary Stent System
9. Atlantis SR Pro Coronary Imaging Catheter
10. Cypher Sirolimus-eluting Coronary Stent
11. Express Coronary Stent System
... 45° Prism are designed for ... recommended for tractional retinal detachments ... retinal detachment. They can be ... other midperipheral laser applications. Direct ...
... The 45° Prism ... fundus pathologies and are ... detachments (PDR, BRVO etc.) ... They can be used ...
... The Chalam 15° Prism are ... and are recommended for tractional ... and Rhegmatogenus retinal detachment. They ... photocoagulation and other midperipheral laser ...
The Mid Field lens can be used for air/gas exchange and has a bi-concave design to provide the widest field available in a direct image surgical lens....
Medicine Products:
(Date:7/25/2014)... July 26, 2014 PersonalInjurySolicitorsIreland, a ... help to people who have suffered from a ... of both their new company, and a website, ... the new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , the ... focus of the company is always on the ...
(Date:7/25/2014)... 25, 2014 American motor vehicle owners ... collisions can pay higher premiums for vehicle insurance on ... insurer network to provide SR22 insurance for high risk ... The different coverage network of local agencies providing direct ... search platform now publicly available for any car owner ...
(Date:7/25/2014)... 2014 Consuming too much salt? Overloaded ... , Read the labels! , Learn to decipher the ... relates to health during a "Healthy Eating for You: ... Humility House, 755 Ohltown Road, Austintown. , Registered dietician ... discussion and answer questions. , The presentation is ...
(Date:7/25/2014)... Island (PRWEB) July 25, 2014 Reproductive ... to announce that Dr. Kerri Luzzo, Lead Physician at ... Award" for her professional accomplishments in fertility care and ... , At the 10th Annual PBN Awards ceremony held ... Island, 40 of the most highly regarded, emerging leaders ...
(Date:7/25/2014)... US (PRWEB) July 25, 2014 ... provider of technology-enabled services for the financial, legal, ... its virtual data room business, Merrill DataSite, has ... Year” presented by GrowthBusiness at the M&A Awards ... recognize the achievements of entrepreneurs, management teams, advisors ...
Breaking Medicine News(10 mins):Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Learn to Decipher Food Labels at Humility House 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2
... interaction with cyclosporine could lead to fatal complications ... People taking the immunosuppressant cyclosporine should avoid consuming ... and possibly lead to deadly consequences, new research ... rats taking cyclosporine -- commonly used to help ...
... 25 NeuroVasx, Inc., a medical device company that ... stroke, announced today that it has received CE Mark ... is a minimally invasive device for the embolization of ... of an artery in the brain. If ruptured, aneurysms ...
... to Assist Processing Plants.SHREVEPORT, La., March 25 Since ... proven to be effective on the poultry processing line ... Salmonella, E. coli , and Listeria . ... help control Campylobacter by pre-screening birds for their current ...
... The 2008 Frost & Sullivan European ... is presented to Ferring Pharmaceuticals. The award ... providing no-needle injection for human growth hormone ... and ZOMAJET VISION X, innovative no-needle delivery ...
... March 25 /PRNewswire-Asia-FirstCall/ -- China Medical,Technologies, Inc. ... a leading China-based,medical device company that develops, ... announced that the Company received,quality testing certificate ... ,SPR System,) from one of the State ...
... March 25 Curemark, LLC, a drug research and ... announced today that the U.S. Food and Drug Administration ... application to initiate its pivotal Phase III clinical trial ... to begin Phase III clinical trials at multiple sites ...
Cached Medicine News:Health News:Licorice May Block Absorption of Organ Transplant Drug 2Health News:NeuroVasx Receives CE Mark for cPAX Aneurysm Treatment System 2Health News:SteriFx Inc. Provides 'Solutions' to Combat Campylobacter 2Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 2Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 3Health News:China Medical Technologies Announces Receipt of SFDA Quality Testing Certificate for its SPR-based Analysis System 2Health News:Curemark Receives Investigational New Drug Clearance for CM-AT for Autism 2Health News:Curemark Receives Investigational New Drug Clearance for CM-AT for Autism 3
(Date:7/24/2014)... Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased by ... Reported sales increased 5% which included a 1% benefit ... as reported (EPS) were $2.49, compared with $2.24 in ... an increase of 9% over the prior-year amount of ...
(Date:7/24/2014)... July 24, 2014 Omnicell, Inc. (NASDAQ: ... medication and supply management solutions and analytics software ... July 31, to discuss the Company,s Second Quarter ... Quarter 2014 earnings conference call and webcastWhen: ... Randall Lipps, chairman, president and chief executive officer ...
(Date:7/24/2014)... VANCOUVER, British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today ... the company,s fiscal year from December 31 to June 30. ... before September 30, 2014. Jeffrey Bacha , ... year end is an important step in achieving our goal ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3